Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Senzime AB ( (SE:SEZI) ) has shared an announcement.
Senzime AB’s annual general meeting approved the 2025 accounts, resolved that no dividend would be paid, and granted discharge from liability to the board and CEO, while setting new cash fees and a share-based Board Program 2026 for directors that includes Class C shares to facilitate share rights delivery. Shareholders re-elected most of the board, added Wolfgang Reim as a new director, renewed the mandate of Öhrlings PricewaterhouseCoopers as auditor, and established rules for a nomination committee ahead of the 2027 meeting.
The meeting amended the articles of association to adjust share capital limits and introduce a new Class C share, adopted a 2026/2030 employee stock option program covering up to 2.64 million options for staff and key individuals, and authorized the board to increase share capital by up to 15 percent through new issues of shares, warrants, or convertibles. These decisions collectively expand Senzime’s flexibility to use equity-based incentives and future capital raisings, supporting its growth strategy while temporarily prioritizing reinvestment over shareholder cash returns.
More about Senzime AB
Senzime AB is a Swedish medical technology company based in Uppsala that develops and markets monitoring solutions for perioperative care. The company focuses on products that enhance patient safety and clinical efficiency, primarily targeting hospitals and surgical environments in its core markets.
Average Trading Volume: 255,502
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK698.8M
For an in-depth examination of SEZI stock, go to TipRanks’ Overview page.